

February 20, 2025

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

**Trading Symbol: ZOTA**

**Sub: Outcome of Board Meeting held on Thursday, February 20, 2025**

**Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject and further to our intimation dated January 09, 2025, pursuant to the approval of the shareholders, and in principle approval of stock exchange, we would like to inform you that the Board of Directors of Zota Health Care Limited (the “Company”) in its meeting held on Thursday, February 20, 2025, at 04:00 P.M. at the Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have, *inter alia*, discussed and approved following businesses:

1. Pursuant to the receipt of the application money i.e. Rs 820/- per equity share, allotment of 7,52,500 (Seven Lakhs Fifty Two Thousand Five Hundred) Equity Shares of face value of Rs. 10/- each at an issue price of Rs. 820/- (Rupees Eight Hundred And Twenty Only) per equity share (including a premium of Rs. 810/- (Rupees Eight Hundred And Ten Only)) aggregating to Rs. 61,70,50,000/- (Rupees Sixty One Crores Seventy Lakhs Fifty Thousand Only) by way of a preferential allotment to the Non Promoter Group Category.

Further, on account of non-subscription of the offer by one of the proposed allottee namely Valiant Mauritius Partners FDI Limited, the Board of Directors of the Company has disposed of the unsubscribed portion to the extent of 3,97,500 equity shares to the said allottee and the offer for issuance and allotment of upto 11,50,000 equity shares on preferential basis to the non-promoter group category has been reduced to such extent.

Equity shares allotted on the preferential basis shall rank *pari passu* with the existing equity shares of the Company in all respects.

Consequent to the aforesaid allotment, the paid-up equity capital of the Company has increased from Rs. 27,88,25,330/- consisting of 2,78,82,533 Equity Shares of Rs.10/- each to Rs. 28,63,50,330/- consisting of 2,86,35,033 Equity Shares of Rs.10/- each.

The requisite disclosure, pursuant to Para A of Part A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as **(Annexure- I)**.

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

2. Pursuant to the receipt of the application money being 25% of the warrant issue price i.e. Rs 205/- per fully convertible warrant aggregating to Rs. 15,42,62,500/- (Rupees Fifteen Crores Forty Two Lakhs Sixty Two Thousand Five Hundred Only), allotment of 7,52,500 (Seven Lakhs Fifty Two Thousand Five Hundred) fully Convertible Warrants (“Warrants”) each convertible into, or exchangeable, at an option of Warrant Holder(s), within a maximum period of 18 (eighteen) months from the date of allotment of warrants into equivalent number of fully paid up equity share of the Company of face value of Rs.10/- (Rupees Ten) each, at an issue price of Rs. 820/- (Rupees Eight Hundred And Twenty Only, (including the warrant subscription price and the warrant exercise price)) each aggregating to an amount of up to Rs. 61,70,50,000/- (Rupees Sixty One Crores Seventy Lakhs Fifty Thousand Only) by way of a preferential allotment to the Non Promoter Group Category.

Further, on account of non-subscription of the offer by one of the proposed allottee namely Valiant Mauritius Partners FDI Limited, the Board of Directors of the Company has disposed of the unsubscribed portion to the extent of 3,97,500 fully convertible warrants to the said allottee and the offer for issuance and allotment of upto 11,50,000 fully convertible warrants on preferential basis to the non-promoter group category has been reduced to such extent.

Equity shares to be allotted on exercise of warrants on the preferential basis shall rank pari passu with the existing equity shares of the Company in all respects.

The requisite disclosure, pursuant to Para A of Part A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as (***Annexure- II***).

The Board meeting concluded at 05:20 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**

Encl: a/a

**Annexure- I**

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015

Disclosure post allotment of Securities by way of preferential issue:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>																								
1	Outcome of the subscription	Allotment of 7,52,500 equity shares for an aggregate consideration of Rs. 61,70,50,000/-																								
2	Issue Price / allotted price (in case of convertibles)	The equity shares are issued at a price of Rs. 820/- each.																								
3	Number of investor(s)	4 (Four) <table border="1"><thead><tr><th><b>SR. NO.</b></th><th><b>NAME OF ALLOTTEES</b></th><th><b>CATEGORY (PROMOTER / NON-PROMOTER)</b></th><th><b>NO OF EQUITY SHARES IN THE COMPANY ALLOTTED</b></th></tr></thead><tbody><tr><td>1</td><td>3P India Equity Fund 1</td><td>Non-Promoter</td><td>4,11,600</td></tr><tr><td>2</td><td>Asha Mukul Agrawal</td><td>Non-Promoter</td><td>1,50,000</td></tr><tr><td>3</td><td>Valiant India Opportunities Ltd</td><td>Non-Promoter</td><td>1,02,500</td></tr><tr><td>4</td><td>3P India Equity Fund 1M</td><td>Non-Promoter</td><td>88,400</td></tr><tr><td colspan="3"><b>TOTAL</b></td><td><b>7,52,500</b></td></tr></tbody></table>	<b>SR. NO.</b>	<b>NAME OF ALLOTTEES</b>	<b>CATEGORY (PROMOTER / NON-PROMOTER)</b>	<b>NO OF EQUITY SHARES IN THE COMPANY ALLOTTED</b>	1	3P India Equity Fund 1	Non-Promoter	4,11,600	2	Asha Mukul Agrawal	Non-Promoter	1,50,000	3	Valiant India Opportunities Ltd	Non-Promoter	1,02,500	4	3P India Equity Fund 1M	Non-Promoter	88,400	<b>TOTAL</b>			<b>7,52,500</b>
<b>SR. NO.</b>	<b>NAME OF ALLOTTEES</b>	<b>CATEGORY (PROMOTER / NON-PROMOTER)</b>	<b>NO OF EQUITY SHARES IN THE COMPANY ALLOTTED</b>																							
1	3P India Equity Fund 1	Non-Promoter	4,11,600																							
2	Asha Mukul Agrawal	Non-Promoter	1,50,000																							
3	Valiant India Opportunities Ltd	Non-Promoter	1,02,500																							
4	3P India Equity Fund 1M	Non-Promoter	88,400																							
<b>TOTAL</b>			<b>7,52,500</b>																							
4	In case of convertibles, intimation on conversion of securities or on lapse of the tenure of the instrument.	Not Applicable																								
5	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable																								

**Annexure- II**

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015

Disclosure post allotment of Securities by way of preferential issue:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>																								
1	Outcome of the subscription	Allotment of 7,52,500 fully convertible warrants each convertible into, or exchangeable convertible into equivalent number of equity shares for an aggregate consideration of Rs. 61,70,50,000/- of which Rs. 15,42,62,500/- (being 25% of the aggregate consideration) has been paid up front.																								
2	Issue Price / allotted price (in case of convertibles)	The warrants are issued at a price of Rs. 820/- each.  An amount equivalent to 25% of the Warrant Issue Price of each warrant has been paid on subscription and allotment of each Warrant.  The balance 75% shall be payable by the warrant holder(s), on exercise of rights attached to the warrants, within a period of 18 months from the date of allotment.																								
3	Number of investor(s)	4 (Four) <table border="1"> <thead> <tr> <th><b>SR. No.</b></th> <th><b>NAME OF ALLOTTEE(S)</b></th> <th><b>CATEGORY (PROMOTER/NON-PROMOTER)</b></th> <th><b>NO OF FULLY CONVERTIBLE WARRANTS IN THE COMPANY ALLOTTED</b></th> </tr> </thead> <tbody> <tr> <td>1</td> <td>3P India Equity Fund 1</td> <td>Non-Promoter</td> <td>4,11,600</td> </tr> <tr> <td>2</td> <td>Asha Mukul Agrawal</td> <td>Non-Promoter</td> <td>1,50,000</td> </tr> <tr> <td>3</td> <td>Valiant India Opportunities Ltd</td> <td>Non-Promoter</td> <td>1,02,500</td> </tr> <tr> <td>4</td> <td>3P India Equity Fund 1M</td> <td>Non-Promoter</td> <td>88,400</td> </tr> <tr> <td colspan="3"><b>TOTAL</b></td> <td><b>7,52,500</b></td> </tr> </tbody> </table>	<b>SR. No.</b>	<b>NAME OF ALLOTTEE(S)</b>	<b>CATEGORY (PROMOTER/NON-PROMOTER)</b>	<b>NO OF FULLY CONVERTIBLE WARRANTS IN THE COMPANY ALLOTTED</b>	1	3P India Equity Fund 1	Non-Promoter	4,11,600	2	Asha Mukul Agrawal	Non-Promoter	1,50,000	3	Valiant India Opportunities Ltd	Non-Promoter	1,02,500	4	3P India Equity Fund 1M	Non-Promoter	88,400	<b>TOTAL</b>			<b>7,52,500</b>
<b>SR. No.</b>	<b>NAME OF ALLOTTEE(S)</b>	<b>CATEGORY (PROMOTER/NON-PROMOTER)</b>	<b>NO OF FULLY CONVERTIBLE WARRANTS IN THE COMPANY ALLOTTED</b>																							
1	3P India Equity Fund 1	Non-Promoter	4,11,600																							
2	Asha Mukul Agrawal	Non-Promoter	1,50,000																							
3	Valiant India Opportunities Ltd	Non-Promoter	1,02,500																							
4	3P India Equity Fund 1M	Non-Promoter	88,400																							
<b>TOTAL</b>			<b>7,52,500</b>																							
4	In case of convertibles, intimation on conversion of securities or on lapse of the tenure of the instrument.	The Warrants may be exercised by the Warrant holder, in one or more tranches, at any time on or before the expiry of 18 months from the date of allotment of the Warrants by issuing a written notice to the Company specifying the number of Warrants proposed to be exercised along with the aggregate amount payable thereon.																								
5	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable																								